Project Grant 1142778

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...

Federal Project Grant Award Summary Haima Therapeutics LLC received a $944,676 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 15, 2025, with a completion date of June 30, 2027. The award supports the development and advancement of Synthoplate (SP), a platelet-inspired synthetic hemostatic nanoparticle designed to restore hemostatic function in traumatic brain injury (TBI) patients...

Federal Grant Award Summary The National Science Foundation (NSF) awarded $305,000 through its Technology, Innovation, and Partnerships program (CFDA 47.084) to Limax Biosciences Inc. for a Phase I Small Business Innovation Research (SBIR) project commencing October 1, 2025 and concluding September 30, 2026. The award supports the development and optimization of HemoMax, a bioinspired hemostatic hydrogel adhesive designed to address uncontrolled bleeding in surgical settings. The hydrogel...

This $999,783 Phase II Small Business Innovation Research (SBIR) cooperative agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Intact Therapeutics' development of a thermogel-based drug delivery platform for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics' proprietary thermogel technology aims to rapidly stop UGIB prior to endoscopic treatment, potentially reducing patient morbidity,...

The U.S. Department of Defense (DoD) Defense Health Agency awarded a $1,820,004 Project Grant to Case Western Reserve University's Office of Research Administration Division, doing business as the University Hospitals of Cleveland, under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," will support the development of an innovative nanoparticle-based technology...

This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $4,000,000.00 in funding to Medcura, Inc. in Riverdale, MD to expand the development and production of a biopolymer powder treatment for noncompressible torso hemorrhage. The research aims to improve health outcomes for military service members and the broader public by advancing this innovative medical technology. The award period extends from Aug 5,...

The U.S. Department of Defense's Defense Health Agency has awarded a $902,109 Project Grant to North Carolina State University (NC State) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "HEMOSEAL: COMBINATORIAL NANOPARTICLE TECHNOLOGY FOR POINT-OF-INJURY HEMORRHAGE CONTROL," supports the development of advanced nanoparticle-based technologies to improve hemorrhage control at the point of injury. The award period runs from July 1, 2024 to...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $350,000 Project Grant to Karios Technologies LLC to develop TissueShield, a novel single-use, ready-to-use, sterile, dual-chamber, dual-syringe sprayable hydrogel for preventing post-surgical cardiac adhesions. TissueShield is a 3-component polymer system that can be easily sprayed directly onto the heart, forming a robust anti-adhesion layer within seconds. The...

Laborecom Therapeutics Inc. received a Phase I Small Business Innovation Research (SBIR) Transition Grant totaling $845,268 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion scheduled for August 31, 2026. The company is developing a novel cell-permeable peptide therapeutic designed to reduce myocardial reperfusion injury in ST-segment elevation myocardial infarction (STEMI)...

The Texas A&M Engineering Experiment Station (Tees) was awarded a $2,404,778 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research and development of expandable hemostats for treatment of noncompressible intracaivitary hemorrhage from August 15, 2022 to August 14, 2026. Through this funding, Tees will investigate medical solutions for uncontrolled bleeding on the battlefield,...